Loading...
XNASTCRT
Market cap492mUSD
Jan 03, Last price  
2.05USD
1D
4.06%
1Q
-22.05%
Jan 2017
-61.68%
Name

Alaunos Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TCRT chart
P/E
—
P/S
98,568.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-59.33%
Rev. gr., 5y
-49.08%
Revenues
5k
-99.83%
0000000667,000800,000800,0001,373,0004,332,0006,861,0006,389,000146,00000398,0002,922,0005,000
Net income
-35m
L-6.54%
-39,166-9,516,923-17,856,919-26,608,246-25,231,000-7,649,000-32,670,000-63,778,000-96,132,000-57,107,000-31,781,000-120,088,000-165,297,000-54,323,000-53,117,000-177,918,000-78,848,000-76,894,000-37,597,000-35,140,000
CFO
-30m
L+3.11%
-7,312-8,780,149-14,421,115-21,650,205-23,519,000-12,294,000-19,694,000-38,835,000-78,832,000-59,509,000-36,650,000-10,000-58,325,000-54,669,000-49,457,000-40,854,000-57,013,000-61,468,000-29,232,000-30,142,000
Earnings
Mar 31, 2025

Profile

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
URL
https://alaunos.com/
IPO date
Aug 20, 2004
Employees
34
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5
-99.83%
2,922
634.17%
Cost of revenue
33,301
40,919
Unusual Expense (Income)
NOPBT
(33,296)
(37,997)
NOPBT Margin
Operating Taxes
(133)
Tax Rate
NOPAT
(33,296)
(37,864)
Net income
(35,140)
-6.54%
(37,597)
-51.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
92
14,679
BB yield
-81.35%
-156.23%
Debt
Debt current
17,323
Long-term debt
4,934
Deferred revenue
Other long-term liabilities
28
Net debt
(6,062)
(16,801)
Cash flow
Cash from operating activities
(30,142)
(29,232)
CAPEX
(197)
(216)
Cash from investing activities
1,346
(193)
Cash from financing activities
(18,138)
6,367
FCF
(15,047)
(40,997)
Balance
Cash
6,062
39,058
Long term investments
Excess cash
6,062
38,912
Stockholders' equity
(915,751)
(880,387)
Invested Capital
922,058
938,481
ROIC
ROCE
EV
Common stock shares outstanding
1,600
14,475
Price
0.07
-89.11%
0.65
-40.45%
Market cap
113
-98.80%
9,396
-39.69%
EV
(5,949)
(7,405)
EBITDA
(30,981)
(35,238)
EV/EBITDA
0.19
0.21
Interest
1,921
3,154
Interest/NOPBT